[144] Insmed, Inc. SEC Filing
Insmed, Inc. (INSM) Form 144 notifies market participants that an insider intends to sell 25,000 shares of common stock through Merrill Lynch on 08/19/2025, with an aggregate market value of $3,188,795.00. The filing shows total outstanding shares of 211,374,786, indicating the proposed sale is a small fraction of the float. The shares to be sold were principally acquired through the company's stock plan between 2020 and 2025, with specific grant lots listed. The filer also reported two recent open-market sales in June 2025 totaling 12,546 shares for gross proceeds of $1,188,677.00. The notice contains the standard attestation that the seller is not aware of undisclosed material adverse information.
Insmed, Inc. (INSM) 鈥� Una Form 144 avvisa il mercato che un insider intende vendere 25.000 azioni ordinarie tramite Merrill Lynch il 19/08/2025, per un valore complessivo di $3.188.795,00. Il documento indica un totale di azioni in circolazione pari a 211.374.786, quindi la vendita proposta rappresenta una piccola frazione del float. Le azioni oggetto della vendita erano state acquisite principalmente tramite il piano azionario della societ脿 tra il 2020 e il 2025, con l鈥檈lenco delle specifiche tranche di assegnazione. Il dichiarante ha inoltre segnalato due vendite in open market a giugno 2025 per un totale di 12.546 azioni, con proventi lordi di $1.188.677,00. L鈥檃vviso include la consueta attestazione secondo cui il venditore non 猫 a conoscenza di informazioni materiali riservate non divulgate.
Insmed, Inc. (INSM) 鈥� Una Form 144 notifica al mercado que un insider planea vender 25.000 acciones ordinarias a trav茅s de Merrill Lynch el 19/08/2025, por un valor agregado de $3.188.795,00. La presentaci贸n muestra un total de acciones en circulaci贸n de 211.374.786, por lo que la venta propuesta es una peque帽a fracci贸n del float. Las acciones a venderse fueron adquiridas principalmente mediante el plan accionarial de la compa帽铆a entre 2020 y 2025, con lotes de asignaci贸n especificados. El declarante tambi茅n report贸 dos ventas recientes en mercado abierto en junio de 2025 por un total de 12.546 acciones y unos ingresos brutos de $1.188.677,00. El aviso contiene la habitual declaraci贸n de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada.
Insmed, Inc. (INSM) 鈥� Form 144鞐� 霐半ゴ氅� 雮措秬鞛愲姅 2025-08-19鞐� Merrill Lynch毳� 韱淀暣 氤错喌欤� 25,000欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜 臧�旃橂姅 $3,188,795.00鞛呺媹雼�. 鞝滌稖靹滊電� 齑� 氚滍枆欤检嫕 靾橁皜 211,374,786欤检瀯鞚� 響滌嫓頃橃棳 鞚措矆 毵る弰電� 鞙犿喌欤检嫕鞚� 鞚茧秬鞐� 攵堦臣頃潉 雮橅儉雰呺媹雼�. 毵る弰 雽�靸� 欤检嫕鞚� 欤茧 須岇偓鞚� 欤检嫕 氤挫儊 頂岆灉鞚� 韱淀暣 2020云勲秬韯� 2025雲� 靷澊鞐� 旆摑霅� 瓴冹溂搿� 韸轨爼 攵�鞐� 雮挫棴鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 霕愴暅 2025雲� 6鞗旍棎 瓿店皽鞁滌灔 毵る弰搿� 12,546欤茧ゼ 觳橂秳頃� 齑� $1,188,677.00鞚� 齑濎垬鞚奠潉 鞓Π 靷嫟鞚� 氤搓碃頄堨姷雼堧嫟. 瓿店碃鞐愲姅 韺愲Г鞛愱皜 牍勱车臧滌潣 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑 氍戈惮臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Insmed, Inc. (INSM) 鈥� Le formulaire 144 informe le march茅 qu鈥檜n initi茅 a l鈥檌ntention de vendre 25 000 actions ordinaires via Merrill Lynch le 19/08/2025, pour une valeur totale de 3 188 795,00 $. Le d茅p么t indique un total d鈥檃ctions en circulation de 211 374 786, ce qui signifie que la vente propos茅e ne repr茅sente qu鈥檜ne faible fraction du flottant. Les actions 脿 vendre ont 茅t茅 principalement acquises dans le cadre du plan d鈥檃ctions de la soci茅t茅 entre 2020 et 2025, avec les lots d鈥檃ttribution sp茅cifi茅s. Le d茅clarant a 茅galement signal茅 deux ventes r茅centes en march茅 ouvert en juin 2025 totalisant 12 546 actions pour des produits bruts de 1 188 677,00 $. L鈥檃vis contient la d茅claration standard selon laquelle le vendeur n鈥檃 pas connaissance d鈥檌nformations d茅favorables importantes non divulgu茅es.
Insmed, Inc. (INSM) 鈥� Eine Form 144 informiert den Markt dar眉ber, dass ein Insider plant, am 19.08.2025 眉ber Merrill Lynch 25.000 Stammaktien zu verkaufen, mit einem Gesamtmarktwert von $3.188.795,00. Die Einreichung weist insgesamt 211.374.786 ausstehende Aktien aus, sodass der geplante Verkauf nur einen kleinen Teil des Free Floats darstellt. Die zu ver盲u脽ernden Aktien wurden haupts盲chlich im Rahmen des Aktienplans des Unternehmens zwischen 2020 und 2025 erworben; konkrete Zuteilungslots sind aufgef眉hrt. Der Melder gab au脽erdem zwei k眉rzliche Verk盲ufe am Markt im Juni 2025 von insgesamt 12.546 Aktien mit Bruttoerl枚sen von $1.188.677,00 an. Die Mitteilung enth盲lt die 眉bliche Erkl盲rung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Full Rule 144 disclosure provided with broker, sale date, and aggregate value
- Securities sourced from company stock plan awards (dates 2020鈥�2025), indicating routine vesting
- Seller attests they are not aware of undisclosed material adverse information
- Insider is selling shares (25,000 planned plus 12,546 sold in June 2025), reflecting ongoing dilution of insider holdings
Insights
TL;DR: Insider intends to sell 25,000 shares (small relative to outstanding shares); recent June sales totaled 12,546 shares.
The proposed 25,000-share sale via Merrill Lynch at an aggregate value of $3.19 million is disclosed under Rule 144 and appears to be sourced from routine stock plan activity spanning 2020鈥�2025. Relative to the issuer's reported outstanding shares (211.37 million), the planned sale represents roughly 0.012% of shares outstanding, which is immaterial from a supply-demand perspective. The two prior sales in June 2025 (10,686 and 1,860 shares) generated $1.19 million, showing the filer has been executing partial disposals over the past month. There is no earnings or operational information in this form to assess company fundamentals.
TL;DR: Filing reflects compliant disclosure of insider sales derived from stock plan awards; no governance red flags visible.
The Form 144 provides required disclosure of the source of shares (stock plan grants) and recent sale activity, and includes the seller's attestation about possession of material non-public information. The schedule of multiple grant dates and small lot sizes suggests routine vesting and planned diversification rather than emergency or undisclosed issues. Absent other disclosures, this filing alone does not signal governance concerns but does document insider liquidity events that investors may note for ownership trends.
Insmed, Inc. (INSM) 鈥� Una Form 144 avvisa il mercato che un insider intende vendere 25.000 azioni ordinarie tramite Merrill Lynch il 19/08/2025, per un valore complessivo di $3.188.795,00. Il documento indica un totale di azioni in circolazione pari a 211.374.786, quindi la vendita proposta rappresenta una piccola frazione del float. Le azioni oggetto della vendita erano state acquisite principalmente tramite il piano azionario della societ脿 tra il 2020 e il 2025, con l鈥檈lenco delle specifiche tranche di assegnazione. Il dichiarante ha inoltre segnalato due vendite in open market a giugno 2025 per un totale di 12.546 azioni, con proventi lordi di $1.188.677,00. L鈥檃vviso include la consueta attestazione secondo cui il venditore non 猫 a conoscenza di informazioni materiali riservate non divulgate.
Insmed, Inc. (INSM) 鈥� Una Form 144 notifica al mercado que un insider planea vender 25.000 acciones ordinarias a trav茅s de Merrill Lynch el 19/08/2025, por un valor agregado de $3.188.795,00. La presentaci贸n muestra un total de acciones en circulaci贸n de 211.374.786, por lo que la venta propuesta es una peque帽a fracci贸n del float. Las acciones a venderse fueron adquiridas principalmente mediante el plan accionarial de la compa帽铆a entre 2020 y 2025, con lotes de asignaci贸n especificados. El declarante tambi茅n report贸 dos ventas recientes en mercado abierto en junio de 2025 por un total de 12.546 acciones y unos ingresos brutos de $1.188.677,00. El aviso contiene la habitual declaraci贸n de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada.
Insmed, Inc. (INSM) 鈥� Form 144鞐� 霐半ゴ氅� 雮措秬鞛愲姅 2025-08-19鞐� Merrill Lynch毳� 韱淀暣 氤错喌欤� 25,000欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜 臧�旃橂姅 $3,188,795.00鞛呺媹雼�. 鞝滌稖靹滊電� 齑� 氚滍枆欤检嫕 靾橁皜 211,374,786欤检瀯鞚� 響滌嫓頃橃棳 鞚措矆 毵る弰電� 鞙犿喌欤检嫕鞚� 鞚茧秬鞐� 攵堦臣頃潉 雮橅儉雰呺媹雼�. 毵る弰 雽�靸� 欤检嫕鞚� 欤茧 須岇偓鞚� 欤检嫕 氤挫儊 頂岆灉鞚� 韱淀暣 2020云勲秬韯� 2025雲� 靷澊鞐� 旆摑霅� 瓴冹溂搿� 韸轨爼 攵�鞐� 雮挫棴鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 霕愴暅 2025雲� 6鞗旍棎 瓿店皽鞁滌灔 毵る弰搿� 12,546欤茧ゼ 觳橂秳頃� 齑� $1,188,677.00鞚� 齑濎垬鞚奠潉 鞓Π 靷嫟鞚� 氤搓碃頄堨姷雼堧嫟. 瓿店碃鞐愲姅 韺愲Г鞛愱皜 牍勱车臧滌潣 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑 氍戈惮臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Insmed, Inc. (INSM) 鈥� Le formulaire 144 informe le march茅 qu鈥檜n initi茅 a l鈥檌ntention de vendre 25 000 actions ordinaires via Merrill Lynch le 19/08/2025, pour une valeur totale de 3 188 795,00 $. Le d茅p么t indique un total d鈥檃ctions en circulation de 211 374 786, ce qui signifie que la vente propos茅e ne repr茅sente qu鈥檜ne faible fraction du flottant. Les actions 脿 vendre ont 茅t茅 principalement acquises dans le cadre du plan d鈥檃ctions de la soci茅t茅 entre 2020 et 2025, avec les lots d鈥檃ttribution sp茅cifi茅s. Le d茅clarant a 茅galement signal茅 deux ventes r茅centes en march茅 ouvert en juin 2025 totalisant 12 546 actions pour des produits bruts de 1 188 677,00 $. L鈥檃vis contient la d茅claration standard selon laquelle le vendeur n鈥檃 pas connaissance d鈥檌nformations d茅favorables importantes non divulgu茅es.
Insmed, Inc. (INSM) 鈥� Eine Form 144 informiert den Markt dar眉ber, dass ein Insider plant, am 19.08.2025 眉ber Merrill Lynch 25.000 Stammaktien zu verkaufen, mit einem Gesamtmarktwert von $3.188.795,00. Die Einreichung weist insgesamt 211.374.786 ausstehende Aktien aus, sodass der geplante Verkauf nur einen kleinen Teil des Free Floats darstellt. Die zu ver盲u脽ernden Aktien wurden haupts盲chlich im Rahmen des Aktienplans des Unternehmens zwischen 2020 und 2025 erworben; konkrete Zuteilungslots sind aufgef眉hrt. Der Melder gab au脽erdem zwei k眉rzliche Verk盲ufe am Markt im Juni 2025 von insgesamt 12.546 Aktien mit Bruttoerl枚sen von $1.188.677,00 an. Die Mitteilung enth盲lt die 眉bliche Erkl盲rung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does the Form 144 filed for INSM report?
How were the shares being sold by the INSM filer acquired?
How large is the proposed sale relative to Insmed芒鈧劉s outstanding shares?
Who is the broker handling the proposed sale?
Did the filer sell any INSM shares recently?
